Physician

Mark S Wallis, M.D.

According to 2025 Medicare claims, Mark Wallis, M.D. (NPI: 1861489049) practices dermatology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is WALLIS DERMATOLOGY ASSOCIATES PLLC (NPI: 1396945234; TIN: 454041922) and primary practice location at 75605-0038.

Wallis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,676 traditional Medicare patients, billed 12,459 HCPCS/CPT codes, and received $767,592 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 741 prescription claims across 346 beneficiaries totaling $329,746 in drug costs, led by Rinvoq (Upadacitinib). Open Payments data shows 112 records totaling $2,136. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $231,515 to $329,746. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,233	10,563	$589,640
2016	1,258	10,575	$555,089
2017	1,675	11,452	$688,624
2018	1,753	20,170	$607,518
2019	1,505	10,466	$546,395
2020	1,478	9,838	$574,200
2021	1,458	10,051	$560,230
2022	1,471	7,562	$510,368
2023	1,511	9,117	$500,925
2024	1,676	12,459	$767,592

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	319	757	$231,515
2016	338	771	$192,703
2017	489	1,059	$224,985
2018	533	1,146	$211,612
2019	478	976	$201,477
2020	325	683	$160,064
2021	317	728	$355,708
2022	355	767	$470,500
2023	396	767	$313,243
2024	346	741	$329,746

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17311	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks	204	270	$463
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	264	347	$56
88305	Pathology examination of tissue using a microscope, intermediate complexity	1,291	2,171	$49
17000	Destruction of precancer skin growth, 1 growth	223	317	$34
17003	Destruction of precancer skin growth, 2-14 growths	193	1,383	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	13	390	$83,897
Sotyktu	Deucravacitinib	11	330	$76,030
Betamethasone Dipropionate	Betamethasone Dipropionate	70	1,814	$2,753
Clobetasol Propionate	Clobetasol Propionate	29	1,094	$1,500
Doxycycline Hyclate	Doxycycline Hyclate	53	2,553	$1,416

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	112	$2,136	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark S. Wallis, M.D.?

Tedicare shows public-source Medicare data for Mark S. Wallis, M.D. (NPI 1861489049), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark S. Wallis, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark S. Wallis, M.D.?

Mark S. Wallis, M.D. is linked to WALLIS DERMATOLOGY ASSOCIATES PLLC (billing NPI 1396945234) in the available physician profile data.

Does Mark S. Wallis, M.D. have Open Payments data?

Mark S. Wallis, M.D. has 112 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.